# Network toxicology reveals key genes of amiodarone induced pulmonary fibrosis: based on machine learning and SHAP analysis

**Authors:** Xiaoyan Yan, Ying Liu, Rui Fan

PMC · DOI: 10.3389/fphar.2026.1755004 · Frontiers in Pharmacology · 2026-02-23

## TL;DR

This study identifies key genes involved in amiodarone-induced pulmonary fibrosis using machine learning and experimental validation, offering new insights into the condition's causes and potential treatments.

## Contribution

The novel contribution is the identification of CTSK, ADORA3, and AGER as key genes in amiodarone-induced pulmonary fibrosis using machine learning and experimental validation.

## Key findings

- CTSK, ADORA3, and AGER were identified as the most important predictors of AIPF using SHAP analysis.
- AMD treatment altered the expression of CTSK, ADORA3, and AGER in bronchial epithelial cells.
- Molecular simulations confirmed stable binding between AMD and the identified target proteins.

## Abstract

Amiodarone (AMD), a highly effective Class III antiarrhythmic drug, has its clinical utility limited by the risk of inducing a serious adverse effect, amiodarone-induced pulmonary fibrosis (AIPF). The pathogenesis of AIPF remains poorly elucidated, particularly the hub driver genes, which hinders early diagnosis and targeted intervention.

This study employed an integrative approach combining network toxicology, machine learning (ML), and in vitro validation to identify hub genes in AIPF. Potential AMD targets and pulmonary fibrosis (PF)-related genes were obtained from toxicity databases and transcriptomic data (GEO datasets), respectively, and intersected to identify candidate AIPF targets. Multiple ML models were constructed, and SHAP (Shapley Additive exPlanations) analysis was used to interpret the model and rank feature importance. Molecular docking and dynamics simulations assessed the binding of AMD to the core targets. Key findings were experimentally validated in an AMD-induced human bronchial epithelial (BEAS-2B) cell model using qRT-PCR, Western blot, and functional assays.

Bioinformatics analysis identified eight candidate hub genes for AIPF. The glmBoost + GBM model demonstrated superior predictive performance (AUC = 0.845). SHAP interpretability analysis identified Cathepsin K (CTSK), Adenosine A3 Receptor (ADORA3), and Advanced Glycosylation End Product-Specific Receptor (AGER) as the most important predictors. Molecular simulations confirmed stable binding between AMD and these target proteins. In vitro experiments showed that AMD treatment significantly upregulated CTSK and downregulated ADORA3 and AGER at both mRNA and protein levels in BEAS-2B cells, and enhanced cell migration and invasion.

This study identifies CTSK, ADORA3, and AGER as key genes in AIPF pathogenesis through a comprehensive bioinformatics and ML approach. Their dysregulation in lung epithelial cells likely promotes fibrosis through modulating extracellular matrix metabolism, inflammation, and cell motility. These findings provide novel insights into AIPF mechanisms and highlight potential biomarkers and therapeutic targets.

## Linked entities

- **Genes:** CTSK (cathepsin K) [NCBI Gene 1513], ADORA3 (adenosine A3 receptor) [NCBI Gene 140], AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177]
- **Chemicals:** amiodarone (PubChem CID 2157)
- **Diseases:** pulmonary fibrosis (MONDO:0002771)

## Full-text entities

- **Genes:** CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, MGP (matrix Gla protein) [NCBI Gene 4256] {aka GIG36, MGLAP, NTI}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, FLT3 (fms related receptor tyrosine kinase 3) [NCBI Gene 2322] {aka CD135, FLK-2, FLK2, STK1}, STATH (statherin) [NCBI Gene 6779] {aka STR}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, TFEB (transcription factor EB) [NCBI Gene 7942] {aka ALPHATFEB, BHLHE35, TCFEB}, CFH (complement factor H) [NCBI Gene 3075] {aka AHUS1, AMBP1, ARMD4, ARMS1, CFHL3, FH}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, SNX9 (sorting nexin 9) [NCBI Gene 51429] {aka SDP1, SH3PX1, SH3PXD3A, WISP}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, SPHK1 (sphingosine kinase 1) [NCBI Gene 8877] {aka SPHK}, COL14A1 (collagen type XIV alpha 1 chain) [NCBI Gene 7373] {aka UND}, AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532] {aka 5-HTT, 5-HTTLPR, 5HTT, HTT, OCD1, SERT}, ADORA3 (adenosine A3 receptor) [NCBI Gene 140] {aka A3AR}, AMD1 (adenosylmethionine decarboxylase 1) [NCBI Gene 262] {aka ADOMETDC, AMD, SAMDC}, CTSS (cathepsin S) [NCBI Gene 1520], MAP3K8 (mitogen-activated protein kinase kinase kinase 8) [NCBI Gene 1326] {aka AURA2, COT, EST, ESTF, MEKK8, TPL2}, ITIH2 (inter-alpha-trypsin inhibitor heavy chain 2) [NCBI Gene 3698] {aka H2P, ITI-HC2, SHAP}, CTSK (cathepsin K) [NCBI Gene 1513] {aka CTS02, CTSO, CTSO1, CTSO2, PKND, PYCD}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, S1PR2 (sphingosine-1-phosphate receptor 2) [NCBI Gene 9294] {aka AGR16, DFNB68, EDG-5, EDG5, Gpcr13, H218}, FLT3LG (fms related receptor tyrosine kinase 3 ligand) [NCBI Gene 2323] {aka FL, FLG3L, FLT3L, IMD125}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, S1PR1 (sphingosine-1-phosphate receptor 1) [NCBI Gene 1901] {aka CD363, CHEDG1, D1S3362, ECGF1, EDG-1, EDG1}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, MBTPS1 (membrane bound transcription factor peptidase, site 1) [NCBI Gene 8720] {aka CAOP, PCSK8, S1P, SEDKF, SKI-1}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, ADRA2B (adrenoceptor alpha 2B) [NCBI Gene 151] {aka ADRA2L1, ADRA2RL1, ADRARL1, ALPHA2BAR, FAME2, alpha-2BAR}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, THBS1 (thrombospondin 1) [NCBI Gene 7057] {aka THBS, THBS-1, TSP, TSP-1, TSP1}, S1PR3 (sphingosine-1-phosphate receptor 3) [NCBI Gene 1903] {aka C9orf108, C9orf47, EDG-3, EDG3, LPB3, S1P3}, SOX9 (SRY-box transcription factor 9) [NCBI Gene 6662] {aka CMD1, CMPD1, ENH13, SRA1, SRXX2, SRXY10}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}
- **Diseases:** systemic sclerosis (MESH:D012595), pulmonary inflammation (MESH:D011014), tumorigenesis (MESH:D063646), FEL (MESH:D011502), ML (MESH:D007859), fatigue (MESH:D005221), arrhythmias (MESH:D001145), respiratory failure (MESH:D012131), lung injury (MESH:D055370), lysosomal (MESH:D016464), Pulmonary Toxicity (MESH:D008171), dyspnea (MESH:D004417), fibrosis (MESH:D005355), inflammation (MESH:D007249), pulmonary hypertension (MESH:D006976), cardiac (MESH:D006331), AIPF (MESH:D011658), interstitial lung diseases (MESH:D017563), collagen (MESH:D003095), Toxicity (MESH:D064420), weight loss (MESH:D015431), pulmonary vascular dysfunction (MESH:D002561), dry cough (MESH:D003371), IPF (MESH:D054990), EndMT (MESH:D008579)
- **Chemicals:** Cyclic Adenosine Monophosphate (MESH:D000242), bleomycin (MESH:D001761), SDS (MESH:D012967), TRIzol (MESH:C411644), Desethylamiodarone (MESH:C036116), phospholipid (MESH:D010743), CCK-8 (MESH:D012844), DAPI (MESH:C007293), 5-HT (MESH:D012701), Hydrogen (MESH:D006859), PVDF (MESH:C024865), PBS (MESH:D007854), paraformaldehyde (MESH:C003043), glutamine (MESH:D005973), AMD (MESH:D000638), asbestos (MESH:D001194), silica (MESH:D012822), S. (MESH:D013455), crystal violet (MESH:D005840), ADM (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A3 adenosine, A2A
- **Cell lines:** BEAS-2B — Homo sapiens (Human), Transformed cell line (CVCL_0168)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968244/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968244/full.md

## References

68 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968244/full.md

---
Source: https://tomesphere.com/paper/PMC12968244